{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:47:09Z","timestamp":1793249229796,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009293","name":"Dementia Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.nbd.2020.104784","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T03:45:21Z","timestamp":1580787921000},"page":"104784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"special_numbering":"C","title":["APOE-amyloid interaction: Therapeutic targets"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-8966","authenticated-orcid":false,"given":"Thomas","family":"Wisniewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.nbd.2020.104784_bb0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","article-title":"2019 Alzheimer\u2019s disease facts and figures","volume":"15","author":"Alzheimer\u2019s Association","year":"2019","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2020.104784_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-019-0611-3","article-title":"Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report","author":"Arboleda-Velasquez","year":"2019","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.nbd.2020.104784_bb0015","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1523\/JNEUROSCI.0887-09.2009","article-title":"Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice","volume":"29","author":"Bales","year":"2009","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.nbd.2020.104784_bb0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ng1197-263","article-title":"Lack of apolipoprotein E dramatically reduces amyloid \u03b2-peptide deposition","volume":"17","author":"Bales","year":"1997","journal-title":"Nat. Gen."},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0025","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3233\/JAD-150136","article-title":"Translation of pre-clinical studies into successful clinical trials for Alzheimer\u2019s disease: what are the roadblocks and how can they be overcome?","volume":"47","author":"Banik","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.nbd.2020.104784_bb0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.jcbfm.9600419","article-title":"Transport pathways for clearance of human Alzheimer\u2019s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system","volume":"27","author":"Bell","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"5","key":"10.1016\/j.nbd.2020.104784_bb0035","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","article-title":"A quarter century of APOE and Alzheimer\u2019s disease: progress to date and the path forward","volume":"101","author":"Belloy","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2020.104784_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/B978-0-12-385883-2.00008-4","article-title":"The genetics of Alzheimer\u2019s disease","volume":"107","author":"Bertram","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.nbd.2020.104784_bb0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"issue":"19","key":"10.1016\/j.nbd.2020.104784_bb0050","doi-asserted-by":"crossref","first-page":"17217","DOI":"10.1074\/jbc.M110.217380","article-title":"Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors","volume":"286","author":"Brodbeck","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.nbd.2020.104784_bb0055","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jalz.2016.01.012","article-title":"Molecular genetics of early-onset Alzheimer\u2019s disease revisited","volume":"12","author":"Cacace","year":"2016","journal-title":"Alzheimers Dement."},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L","article-title":"Apolipoprotein J (clusterin) and Alzheimer\u2019s disease","volume":"50","author":"Calero","year":"2000","journal-title":"Microsc. Res. Tech."},{"issue":"Pt 2","key":"10.1016\/j.nbd.2020.104784_bb0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1042\/bj3060599","article-title":"Fibrillogenesis in Alzheimer\u2019s disease of amyloid beta peptides and apolipoprotein E","volume":"306","author":"Castano","year":"1995","journal-title":"Biochem. J."},{"issue":"89","key":"10.1016\/j.nbd.2020.104784_bb0070","doi-asserted-by":"crossref","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","article-title":"Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance","volume":"3","author":"Castellano","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.nbd.2020.104784_bb0075","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1096\/fj.10-175976","article-title":"High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer\u2019s disease","volume":"25","author":"Cerf","year":"2011","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.nbd.2020.104784_bb0080","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1074\/jbc.M111.276162","article-title":"Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons","volume":"287","author":"Chen","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.nbd.2020.104784_bb0085","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neurobiolaging.2006.12.013","article-title":"The impact of apolipoprotein E on dementia in persons with Down\u2019s syndrome","volume":"29","author":"Coppus","year":"2008","journal-title":"Neurobiol. Aging"},{"issue":"5123","key":"10.1016\/j.nbd.2020.104784_bb0090","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science."},{"key":"10.1016\/j.nbd.2020.104784_bb0095","author":"Crystal"},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"issue":"8","key":"10.1016\/j.nbd.2020.104784_bb0105","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S1474-4422(16)00127-7","article-title":"Genetic variations underlying Alzheimer\u2019s disease: evidence from genome-wide association studies and beyond","volume":"15","author":"Cuyvers","year":"2016","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0110","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/cb500994j","article-title":"Chemical cross-linking\/mass spectrometry maps the amyloid beta peptide binding region on both apolipoprotein E domains","volume":"10","author":"Deroo","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.nbd.2020.104784_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-018-0074-z","article-title":"A cross-species approach to disorders affecting brain and behaviour","author":"Devinsky","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0120","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1073\/pnas.0409072102","article-title":"Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer\u2019s disease","volume":"102","author":"Dodart","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","article-title":"Alzheimer\u2019s disease: experimental models and reality","volume":"133","author":"Drummond","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.nbd.2020.104784_bb0130","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Proceedings of the Meeting of the International Working G, the American Alzheimer\u2019s Association on The Preclinical State of AD, July, Washington DC USA. Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ng0594-74","article-title":"Apolipoprotein E4 allele in a population-based study of early- onset Alzheimer\u2019s disease","volume":"7","author":"van Duijn","year":"1994","journal-title":"Nat. Gen."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13024-017-0184-x","article-title":"Late onset Alzheimer\u2019s disease genetics implicates microglial pathways in disease risk","volume":"12","author":"Efthymiou","year":"2017","journal-title":"Mol. Neurodegener."},{"issue":"3","key":"10.1016\/j.nbd.2020.104784_bb0145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3233\/JAD-190507","article-title":"Developing effective Alzheimer\u2019s disease therapies: clinical experience and future directions","volume":"71","author":"Elmaleh","year":"2019","journal-title":"J. Alzheimers Dis."},{"issue":"21","key":"10.1016\/j.nbd.2020.104784_bb0150","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1523\/JNEUROSCI.23-21-07889.2003","article-title":"Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice","volume":"23","author":"Fryer","year":"2003","journal-title":"J. Neurosci."},{"issue":"40","key":"10.1016\/j.nbd.2020.104784_bb0155","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1021\/bi5008172","article-title":"The binding of apolipoprotein E to oligomers and fibrils of amyloid-beta alters the kinetics of amyloid aggregation","volume":"53","author":"Garai","year":"2014","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"10.1016\/j.nbd.2020.104784_bb0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0304-3940(95)11565-7","article-title":"Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid","volume":"191","author":"Golabek","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2020.104784_bb0165","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1074\/jbc.271.18.10602","article-title":"The interaction between apolipoprotein E and Alzheimer\u2019s amyloid \u03b2-peptide is dependent on \u03b2-peptide conformation","volume":"271","author":"Golabek","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0170","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s13311-014-0295-9","article-title":"Genetics of Alzheimer\u2019s disease","volume":"11","author":"Guerreiro","year":"2014","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.nbd.2020.104784_bb0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2015.12.004","article-title":"Amyloid beta-interacting partners in Alzheimer\u2019s disease: from accomplices to possible therapeutic targets","volume":"137","author":"Han","year":"2016","journal-title":"Prog. Neurobiol."},{"issue":"6","key":"10.1016\/j.nbd.2020.104784_bb0180","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jalz.2014.10.007","article-title":"Down syndrome and Alzheimer\u2019s Disease: common pathways, common goals","volume":"11","author":"Hartley","year":"2015","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"43","key":"10.1016\/j.nbd.2020.104784_bb0185","doi-asserted-by":"crossref","first-page":"15181","DOI":"10.1523\/JNEUROSCI.1542-12.2012","article-title":"Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide","volume":"32","author":"Hashimoto","year":"2012","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1567205012666151020114607","article-title":"Aging in Down syndrome and the development of Alzheimer\u2019s disease neuropathology","volume":"13","author":"Head","year":"2016","journal-title":"Curr. Alzheimer Res."},{"issue":"8","key":"10.1016\/j.nbd.2020.104784_bb0195","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14760584.2018.1500905","article-title":"Recent advancements toward therapeutic vaccines against Alzheimer\u2019s disease","volume":"17","author":"Herline","year":"2018","journal-title":"Expert Rev. Vaccin."},{"issue":"8","key":"10.1016\/j.nbd.2020.104784_bb0200","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2174\/138161212799315885","article-title":"Nonhuman primate models of Alzheimer-like cerebral proteopathy","volume":"18","author":"Heuer","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.nbd.2020.104784_bb0205","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.050004797","article-title":"Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer\u2019s disease","volume":"97","author":"Holtzman","year":"2000","journal-title":"PNAS."},{"issue":"24","key":"10.1016\/j.nbd.2020.104784_bb0210","doi-asserted-by":"crossref","first-page":"15163","DOI":"10.1074\/jbc.M114.622209","article-title":"Role of Apolipoprotein E in beta-Amyloidogenesis: isoform-specific effects on protofibril to fibril conversion of abeta in vitro and brain abeta deposition in vivo","volume":"290","author":"Hori","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0215","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1021\/acs.jmedchem.6b01437","article-title":"Recent advances in scaffold hopping","volume":"60","author":"Hu","year":"2017","journal-title":"J. Med. Chem."},{"issue":"Pt A","key":"10.1016\/j.nbd.2020.104784_bb0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer\u2019s diseases","volume":"72","author":"Huang","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"212","key":"10.1016\/j.nbd.2020.104784_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007000","article-title":"Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain","volume":"5","author":"Hudry","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0230","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900325","article-title":"Opposing roles of apolipoprotein E in aging and neurodegeneration","volume":"2","author":"Hudry","year":"2019","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.nbd.2020.104784_bb0235","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.R075481","article-title":"Apolipoprotein E and Alzheimer disease: the influence of apoE on amyloid-beta and other amyloidogenic proteins","author":"Huynh","year":"2017","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.nbd.2020.104784_bb0240","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1073\/pnas.92.8.3586","article-title":"Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome)","volume":"92","author":"Hyman","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.nbd.2020.104784_bb0245","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","article-title":"Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk","volume":"51","author":"Jansen","year":"2019","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuron.2014.05.041","article-title":"Alzheimer\u2019s disease genetics: from the bench to the clinic","volume":"83","author":"Karch","year":"2014","journal-title":"Neuron."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0255","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","article-title":"Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis","volume":"77","author":"Karch","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.gene.2014.05.031","article-title":"Genetic markers for diagnosis and pathogenesis of Alzheimer\u2019s disease","volume":"545","author":"Kim","year":"2014","journal-title":"Gene."},{"issue":"12","key":"10.1016\/j.nbd.2020.104784_bb0265","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1084\/jem.20121274","article-title":"Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis","volume":"209","author":"Kim","year":"2012","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0270","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12779\/dnd.2018.17.4.131","article-title":"Genetics of Alzheimer\u2019s disease","volume":"17","author":"Kim","year":"2018","journal-title":"Dement. Neurocogn. Disord."},{"issue":"Pt 7","key":"10.1016\/j.nbd.2020.104784_bb0275","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/brain\/aws127","article-title":"Apolipoprotein E4 effects in Alzheimer\u2019s disease are mediated by synaptotoxic oligomeric amyloid-beta","volume":"135","author":"Koffie","year":"2012","journal-title":"Brain."},{"issue":"3","key":"10.1016\/j.nbd.2020.104784_bb0280","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0285","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.nbd.2020.104784_bb0290","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/sj.mp.4001083","article-title":"APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss","volume":"7","author":"Laws","year":"2002","journal-title":"Mol. Psychiatry"},{"issue":"21","key":"10.1016\/j.nbd.2020.104784_bb0295","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","article-title":"Anti-ApoE antibody given after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of Abeta amyloidosis","volume":"34","author":"Liao","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.104784_bb0300","article-title":"Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation","author":"Liao","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.nbd.2020.104784_bb0305","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1212\/WNL.0000000000004336","article-title":"APOE genotype and early beta-amyloid accumulation in older adults without dementia","volume":"89","author":"Lim","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nbd.2020.104784_bb0310","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.neuron.2018.06.011","article-title":"APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types","volume":"98","author":"Lin","year":"2018","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.nbd.2020.104784_bb0315","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1039\/c1mb05019b","article-title":"Mapping ApoE\/Abeta binding regions to guide inhibitor discovery","volume":"7","author":"Liu","year":"2011","journal-title":"Mol. BioSyst."},{"issue":"577","key":"10.1016\/j.nbd.2020.104784_bb0320","first-page":"591","article-title":"Blocking the apolipoprotein E\/amyloid \u03b2-interaction in triple transgenic mice ameliorates Alzheimer\u2019s disease related amyloid \u03b2 and tau pathology","volume":"128","author":"Liu","year":"2014","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0325","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1038\/s41598-017-08604-8","article-title":"Targeting apolipoprotein E\/amyloid \u03b2 binding by peptoid CPO_A\u03b217-21P ameliorates Alzheimer\u2019s disease related pathology and cognitive decline","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2020.104784_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: An update on pathobiology and treatment strategies","author":"Long","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000663","article-title":"In silico analysis of the apolipoprotein E and the amyloid beta peptide interaction: misfolding induced by frustration of the salt bridge network","volume":"6","author":"Luo","year":"2010","journal-title":"PLoS Comput. Biol."},{"issue":"5","key":"10.1016\/j.nbd.2020.104784_bb0340","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0197-4580(96)00112-1","article-title":"Alzheimer A\u03b2 neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A\u03b2-related peptides","volume":"17","author":"Ma","year":"1996","journal-title":"Neurobiol. Aging"},{"issue":"6501","key":"10.1016\/j.nbd.2020.104784_bb0345","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/372092a0","article-title":"Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments","volume":"372","author":"Ma","year":"1994","journal-title":"Nature."},{"issue":"21","key":"10.1016\/j.nbd.2020.104784_bb0350","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1021\/jm3008618","article-title":"Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology","volume":"55","author":"Mahley","year":"2012","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.nbd.2020.104784_bb0355","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaneurol.2014.2011","article-title":"Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function","volume":"71","author":"Mak","year":"2014","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.nbd.2020.104784_bb0360","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/00001756-199507310-00012","article-title":"ApoE genotypes in Australia: roles in early and late onset Alzheimer\u2019s disease and Down\u2019s syndrome","volume":"6","author":"Martins","year":"1995","journal-title":"Neuroreport."},{"issue":"3","key":"10.1016\/j.nbd.2020.104784_bb0365","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3233\/JAD-171145","article-title":"Alzheimer\u2019s disease: a journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies-gains from AIBL and DIAN cohort studies","volume":"62","author":"Martins","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"13","key":"10.1016\/j.nbd.2020.104784_bb0370","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1074\/jbc.270.13.7563","article-title":"Characterization of apolipoprotein J-Alzheimer\u2019s A beta interaction","volume":"270","author":"Matsubara","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.104784_bb0375","doi-asserted-by":"crossref","unstructured":"Medway CW, Abdul-Hay S, Mims T, Ma L, Bisceglio G, Zou F, Pankratz S, Sando SB, Aasly JO, Barcikowska M, Siuda J, Wszolek ZK, Ross OA, Carrasquillo M, Dickson DW, Graff-Radford N, Petersen RC, Ertekin-Taner N, Morgan K, Bu G, Younkin SG. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol. Neurodegener. 2014;9:11. Epub 2014\/03\/13. doi: https:\/\/doi.org\/10.1186\/1750-1326-9-11. (PubMed PMID: 24607147; PMCID: PMC3995879).","DOI":"10.1186\/1750-1326-9-11"},{"issue":"27","key":"10.1016\/j.nbd.2020.104784_bb0380","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1523\/JNEUROSCI.1306-05.2005","article-title":"Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice","volume":"25","author":"Miao","year":"2005","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0385","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/0014-5793(95)01491-8","article-title":"Cerebrovascular amyloidosis in squirrel monkeys and rhesus monkeys: apolipoprotein E genotype","volume":"379","author":"Morelli","year":"1996","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0390","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.21843","article-title":"APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging","volume":"67","author":"Morris","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2020.104784_bb0395","first-page":"75","article-title":"Blocking the apoE\/Abeta interaction ameliorates Abeta-related pathology in APOE epsilon2 and epsilon4 targeted replacement Alzheimer model mice","volume":"2","author":"Pankiewicz","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2020.104784_bb0400","article-title":"Untangling genetic risk for Alzheimer\u2019s disease","author":"Pimenova","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.nbd.2020.104784_bb0405","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neurobiolaging.2018.07.007","article-title":"The spectrum of preclinical Alzheimer\u2019s disease pathology and its modulation by ApoE genotype","volume":"71","author":"Pletnikova","year":"2018","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"10.1016\/j.nbd.2020.104784_bb0410","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0197-4580(01)00308-6","article-title":"The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation","volume":"22","author":"Potter","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2020.104784_bb0415","first-page":"489428","article-title":"Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade","author":"Potter","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0420","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/CON.0000000000000700","article-title":"Late-onset Alzheimer disease","volume":"25","author":"Rabinovici","year":"2019","journal-title":"Continuum (Minneap Minn)."},{"issue":"8","key":"10.1016\/j.nbd.2020.104784_bb0425","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.neurobiolaging.2015.04.001","article-title":"Changes in Abeta biomarkers and associations with APOE genotype in 2 longitudinal cohorts","volume":"36","author":"Resnick","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0430","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-180740","article-title":"The role of apolipoprotein E isoforms in Alzheimer\u2019s disease","volume":"68","author":"Roda","year":"2019","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0435","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.nbd.2020.104784_bb0440","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1749-6632.1996.tb34428.x","article-title":"ApoE2 allele, Down\u2019s syndrome, and dementia","volume":"777","author":"Royston","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"49","key":"10.1016\/j.nbd.2020.104784_bb0445","doi-asserted-by":"crossref","first-page":"18787","DOI":"10.1073\/pnas.0604011103","article-title":"Blocking the apolipoproteinE\/Amyloid \u03b2 interaction reduces the parenchymal and vascular amyloid-\u03b2 deposition and prevents memory deficit in AD transgenic mice","volume":"103","author":"Sadowski","year":"2006","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.nbd.2020.104784_bb0450","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0002-9440(10)63355-X","article-title":"A synthetic peptide blocking the apolipoprotein E\/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice","volume":"165","author":"Sadowski","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0455","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12916-019-1299-4","article-title":"ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease","volume":"17","author":"Safieh","year":"2019","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0460","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1172\/JCI117407","article-title":"Apolipoprotein E associates with beta amyloid peptide of Alzheimer\u2019s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3","volume":"94","author":"Sanan","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"9020","key":"10.1016\/j.nbd.2020.104784_bb0465","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0140-6736(96)01251-2","article-title":"Specificity, sensitivity, and predictive value of apolipoprotein- E genotyping for sporadic Alzheimer\u2019s disease","volume":"348","author":"Saunders","year":"1996","journal-title":"Lancet."},{"issue":"10043","key":"10.1016\/j.nbd.2020.104784_bb0470","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet."},{"issue":"20","key":"10.1016\/j.nbd.2020.104784_bb0475","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.90.20.9649","article-title":"Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease","volume":"90","author":"Schmechel","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.nbd.2020.104784_bb0480","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.nbd.2020.104784_bb0485","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.nbd.2020.104784_bb0490","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The role of amyloid-beta oligomers in toxicity, propagation, and immunotherapy","volume":"6","author":"Sengupta","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.nbd.2020.104784_bb0495","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-018-0051-1","article-title":"Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight","author":"Shi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0500","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ana.410380120","article-title":"Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer\u2019s disease","volume":"38","author":"Sorbi","year":"1995","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2020.104784_bb0505","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","article-title":"Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.nbd.2020.104784_bb0510","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","article-title":"Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.nbd.2020.104784_bb0515","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A beta-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0520","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/nan.12529","article-title":"Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer\u2019s disease","volume":"45","author":"Tzioras","year":"2019","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0525","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuron.2017.02.042","article-title":"Elucidating the role of TREM2 in Alzheimer\u2019s disease","volume":"94","author":"Ulrich","year":"2017","journal-title":"Neuron."},{"issue":"7","key":"10.1016\/j.nbd.2020.104784_bb0530","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/mp.2015.177","article-title":"APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer\u2019s disease","volume":"21","author":"Velez","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"19","key":"10.1016\/j.nbd.2020.104784_bb0535","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1220484110","article-title":"ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE\/Abeta association in physiological conditions","volume":"110","author":"Verghese","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0540","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid beta oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.nbd.2020.104784_bb0545","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.molmed.2017.04.001","article-title":"The exceptional vulnerability of humans to Alzheimer\u2019s disease","volume":"23","author":"Walker","year":"2017","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.nbd.2020.104784_bb0550","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","article-title":"Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector","volume":"24","author":"Wang","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0555","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajmg.b.30087","article-title":"APOE and other loci affect age-at-onset in Alzheimer\u2019s disease families with PS2 mutation","volume":"132B","author":"Wijsman","year":"2005","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0560","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneurol.2011.221","article-title":"Autosomal recessive causes likely in early-onset Alzheimer disease","volume":"69","author":"Wingo","year":"2012","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2020.104784_bb0565","first-page":"1030","article-title":"Acceleration of Alzheimer\u2019s fibril formation by apolipoprotein E in vitro","volume":"145","author":"Wisniewski","year":"1994","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2020.104784_bb0570","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/bs.pmbts.2019.08.001","article-title":"Future horizons in Alzheimer\u2019s disease research","volume":"168","author":"Wisniewski","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0575","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0304-3940(92)90444-C","article-title":"Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid","volume":"135","author":"Wisniewski","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2020.104784_bb0580","first-page":"171","article-title":"Apolipoprotein E, amyloidosis and Alzheimer\u2019s disease","volume":"10","author":"Wisniewski","year":"1996","journal-title":"Dementia."},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0585","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0197-4580(94)90105-8","article-title":"Alzheimer\u2019s disease and soluble A\u03b2","volume":"15","author":"Wisniewski","year":"1994","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0590","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1006\/bbrc.1993.1423","article-title":"Apolipoprotein E: binding to soluble Alzheimer\u2019s beta-amyloid","volume":"192","author":"Wisniewski","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8955","key":"10.1016\/j.nbd.2020.104784_bb0595","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(95)90701-7","article-title":"Is Alzheimer\u2019s disease an apolipoprotein E amyloidosis?","volume":"345","author":"Wisniewski","year":"1995","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.nbd.2020.104784_bb0600","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410370128","article-title":"The influence of apolipoprotein E isotypes on Alzheimer\u2019s disease pathology in 40 cases of Down\u2019s syndrome","volume":"37","author":"Wisniewski","year":"1995","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.nbd.2020.104784_bb0605","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JAD-2011-101401","article-title":"Blocking the apolipoprotein E\/amyloid \u03b2 interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice","volume":"24","author":"Yang","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2020.104784_bb0610","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-019-0634-9","article-title":"An Alzheimer\u2019s-disease-protective APOE mutation","author":"Zalocusky","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2020.104784_bb0615","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2016.04.020","article-title":"Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models","volume":"44","author":"Zhao","year":"2016","journal-title":"Neurobiol. Aging"},{"issue":"4","key":"10.1016\/j.nbd.2020.104784_bb0620","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.biopsych.2017.03.003","article-title":"Apolipoprotein E, receptors, and modulation of Alzheimer\u2019s disease","volume":"83","author":"Zhao","year":"2018","journal-title":"Biol. Psychiatry"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996120300590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996120300590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:16:57Z","timestamp":1760851017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996120300590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":124,"alternative-id":["S0969996120300590"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2020.104784","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"APOE-amyloid interaction: Therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2020.104784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104784"}}